Department of Neurosurgery, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey.
Cukurova University, Biotechnology Center, Adana, Turkey.
Anticancer Agents Med Chem. 2021;21(15):2032-2040. doi: 10.2174/1871520621666210211163055.
Oxidative stress that leads to an imbalanced prooxidant/antioxidant status can be a critical factor affecting lung cancer etiopathology. The antioxidant system provides primary protection under oxidative stress.
The purpose of the study was to investigate the serum antioxidant system status in brain metastatic and non-metastatic lung cancer patients with different cell types.
In this prospective study, 33 patients with lung cancer metastasis (metastatic patient group), 36 lung cancer patients (non-metastatic patient group), and 25 healthy control groups were included. Enzymatic (Superoxide Dismutase, SOD; Glutathione Peroxidase, GPX; and Glutathione Reductase, GR) and non-enzymatic (Glutathione, GSH) antioxidant system biomarkers with Thiobarbituric Acid Reactive Substances (TBARS) levels were studied in the serum samples of the control and patient groups. The oxidative stress biomarkers were measured spectrophotometrically.
SOD activity increased though TBARS levels and GR activity decreased in both patient groups compared to the control. GPX activity increased only in the non-metastatic group. Antioxidant biomarkers varied between small cell and non-small cell group patients. GR activity and GSH levels were significantly higher in the non-metastatic group compared to the metastatic group. Correlations were also found between antioxidant parameters in the non-metastatic group.
It was emphasized the imbalanced antioxidant system in the duration of the disease is related to not only cell type but also the metastatic structure. This is the preliminary study exhibiting the contribution of antioxidant imbalance in different subtypes with varied prognosis and behavior of lung cancer in the presence of brain metastasis. Therefore, oxidative stress biomarkers can serve as a useful tool to get information about the progression of lung cancer. Thus, it may provide fundamental data for further cancer research when considering the diagnosis of the disease.
导致促氧化剂/抗氧化剂状态失衡的氧化应激可能是影响肺癌发病机制的关键因素。抗氧化系统在氧化应激下提供主要保护。
本研究旨在探讨不同细胞类型的脑转移和非转移肺癌患者血清抗氧化系统状态。
在这项前瞻性研究中，纳入了 33 例肺癌转移患者（转移患者组）、36 例肺癌患者（非转移患者组）和 25 名健康对照组。在对照组和患者组的血清样本中研究了酶（超氧化物歧化酶、SOD；谷胱甘肽过氧化物酶、GPX；和谷胱甘肽还原酶、GR）和非酶（谷胱甘肽、GSH）抗氧化系统生物标志物与硫代巴比妥酸反应物质（TBARS）水平。氧化应激生物标志物通过分光光度法进行测量。
与对照组相比，两组患者的 SOD 活性增加，TBARS 水平和 GR 活性降低。只有非转移组的 GPX 活性增加。非小细胞肺癌和小细胞肺癌患者的抗氧化生物标志物不同。与转移组相比，非转移组的 GR 活性和 GSH 水平显著更高。在非转移组中还发现了抗氧化参数之间的相关性。
疾病持续时间内不平衡的抗氧化系统不仅与细胞类型有关，而且与转移结构有关。这是初步研究，展示了不同亚型中抗氧化失衡对肺癌的存在脑转移的不同预后和行为的贡献。因此，氧化应激生物标志物可以作为了解肺癌进展的有用工具。因此，当考虑疾病诊断时，它可能为进一步的癌症研究提供基础数据。
